N/A
N=21
Gene Expression Study Between Two Dermal Injectables Hydroxylapatite Semi-permanent Filler
Gene Expression
Bottom Line
View on ClinicalTrials.gov: NCT05620043 ↗Enrolled (actual)
21
Serious AEs
0.0%
Results posted
Apr 2026
Primary outcome: Primary: Gene Expression — 1; 1; 1; 4 Significantly upregulated genes
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Sculptra (Device); Radiesse Plus (Device)
- Age
- Adult · 22+ yrs
- Sex
- All
- Sponsor
- Galderma R&D
- Primary completion
- Jul 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Gene Expression |
1; 1; 1; 4; 2; 2 | — |
Summary
To compare gene expression stimulated by a semi-permanent filler and a biostimulator via punch biopsy
Eligibility Criteria
Inclusion Criteria
- Subject with a minimum of shallow nasolabial fold (NLF) contour deficiencies as assessed via the wrinkle assessment scale
- Subject with identical WAS scores on both NLFs
- Ability of giving consent for participation in the study
- Agreement to have skin biopsies on NLFs
Exclusion Criteria
- Significant NLF asymmetry, or different WAS score on each NLF
- Pregnant, planning pregnancy during the course of the study or breastfeeding
- History of allergy or hypersensitivity to any ingredient of the treatment products
- History of allergy or hypersensitivity to anesthetics or lidocaine
Data sourced from ClinicalTrials.gov (NCT05620043). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.